Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

Multiple myeloma (MM) is an incurable malignancy with an unmet need for innovative treatment options. Histone deacetylase inhibitors (HDACi) are a new class of anticancer agent that have demonstrated activity in hematological malignancies. Here, we investigated the efficacy and safety of HDACi (vori...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Matthews, G M, Lefebure, M, Doyle, M A, Shortt, J, Ellul, J, Chesi, M, Banks, K-M, Vidacs, E, Faulkner, D, Atadja, P, Bergsagel, P L, Johnstone, R W
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2013
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3789166/
https://ncbi.nlm.nih.gov/pubmed/24030150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2013.306
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia